Pharvaris N.V. (PHVS)
PHVS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | PHVS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Netherlands |
| IPO year | 2021 |
| SEC CIK | 0001830487 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Netherlands |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-04-02 |
| Cash and burn | $322.4M cash; operating cash flow -$37.9M a quarter. | Report 2025-12-31 |
| Shares outstanding | 65,210,590 (2025-12-31); 54,379,491 a year earlier; 33,816,459 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-05-08 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers Accountants N.V., Amsterdam, Netherlands | PCAOB Form AP 2026-05-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $32.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$194.2M | -$151.5M | $322.4M | No debt tags | Needs four quarters | 20-F 2026-04-02 |
| FY 2020 2020-12-31 | Not filed | -$26.0M | Not filed | Not filed | No debt tags | Needs four quarters | 20-F 2021-04-29 |
| FY 2019 2019-12-31 | Not filed | -$8.0M | Not filed | Not filed | No debt tags | Needs four quarters | 20-F 2021-04-29 |
| FY 2018 2018-12-31 | Not filed | -$4.3M | Not filed | Not filed | No debt tags | Needs four quarters | 20-F 2021-04-29 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-08 |
| Latest annual report | 20-F | 2026-04-02 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 331 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -3.0% |
| 1 month | +11.1% |
| 3 months | -2.0% |
| Year to date | +20.2% |
| 1 year | +37.5% |
| From 52-week high | -14.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PRGO | Perrigo Company plc | $16.18 | -0.37% | $2.2B |
| PBH | Prestige Consumer Healthcare Inc. | $48.00 | +3.92% | $2.3B |
| LKFT | Lakefront Biotherapeutics | $34.79 | +2.38% | $2.3B |
| NAMS | NewAmsterdam Pharma Company N.V. | $19.46 | -3.38% | $2.3B |
| PVLA | Palvella Therapeutics Inc. | $144.60 | -5.17% | $2.1B |
| RCUS | Arcus Biosciences Inc. | $16.86 | -3.27% | $2.4B |
| BHVN | Biohaven Ltd. Common Shares | $13.80 | -0.14% | $2.1B |
| IMNM | Immunome Inc. | $17.61 | -6.18% | $2.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier